We identified a significant downregulation in PRODH expression in combined and chronic phase CML samples (Figure 5A, PComb = 4.6 × 10−2, PChronic = 9.4 × 10−3), and significant upregulations in AST1 (Figure 5B, PComb = 0.02, PChronic = 0.03), GPT/ALT1 (Figure 5C, PComb = 0.03; PChronic = 0.04), ASNS (Figure 5D, PComb = 0.04; PChronic = 0.02), and CTH (Figure 5E, PComb = 3 × 10−4; PChronic <1 × 10−4) in the combined and chronic phase CML sample analysis. The gene discussed is PRODH; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.